Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

FDA Approves New HIV-Prevention Drug, but Not for Women

FDA Approves New HIV-Prevention Drug, but Not for Women

The Food and Drug Administration on Thursday approved a new drug, Descovy, for prevention of infection with HIV, only the second drug approved for this purpose.The first, Truvada, has become a mainstay of government efforts to turn back the HIV epidemic. But the FDA approved Descovy for use only in men
The Food and Drug Administration on Thursday approved a new drug, Descovy, for prevention of infection with HIV, only the second drug approved for this purpose.

The first, Truvada, has become a mainstay of government efforts to turn back the HIV epidemic. But the FDA approved Descovy for use only in men and transgender women, because its maker, Gilead Sciences, tested it only in those groups.

The approval explicitly excludes women and does not outline a plan for making the drug available to them. Some activists and scientists said the approval sets a dangerous precedent by allowing companies to dodge expensive trials needed to test medicines in women.

Such an exclusion of women “should be unacceptable in these days and times,” said Dr. Rochelle Walensky, chief of infectious diseases at Massachusetts General Hospital.

It’s important to test the drug specifically in women, she added, because Descovy may work differently in the vagina than in rectal tissues.

The FDA, in fact, will require Gilead to study Descovy in women, company officials said. Gilead is considering a trial in Africa.

Gilead also makes Truvada. Both medicines are to be taken daily, an HIV-prevention strategy called preexposure prophylaxis, or PrEP.

The company has come under heavy criticism for selling Truvada at a high cost, currently about $20,000 a year. Critics have said the expense keeps the drug out of reach of Americans who would benefit from it. Few patients actually pay the full price, Gilead has said.

Less expensive generic versions of Truvada are expected next year, as the drug’s patent protections expire. But Descovy’s approval ensures Gilead’s continued dominance of the market for PrEP, said Jeremiah Johnson, a project director at Treatment Action Group, an advocacy organization.

Descovy is not more effective than Truvada, Johnson noted. But in various presentation materials, Gilead on occasion has hinted that it is, and Johnson and others fear patients may reject affordable and accessible generic versions of Truvada in favor of the more expensive Descovy.

Any suggestion that Descovy is more effective than Truvada was unintentional, said Diana Brainard, who oversees Gilead’s HIV division. The company’s message, she added, is that both Descovy and Truvada are highly effective at preventing HIV infection when taken daily.

“It’s always good to have choice,” she said.

Descovy’s patent is supposed to expire in 2026, but a nonprofit group called Prep4All Collaboration hopes to find a way to end it in 2022.

The group had been running a campaign called “Break the Patent” to limit Truvada’s patent protection, which was supposed to expire in 2021. But in May, Gilead announced that a generic version would be available next year.

“As of today, we’re adding an ‘s’ — it’s ‘Break the Patents,’ ” said Peter Staley, a founder of the collaboration.

Descovy contains a newer version of tenofovir, the active ingredient in Truvada. Gilead tested Descovy in a multinational trial that included 5,313 men and 74 transgender women who have sex with men. There were no cisgender women, and 84% of the participants were white.

“They did a terrible job of inclusion for a company that dominates the market,” Johnson said.

There are some data suggesting that Descovy has fewer side effects on bones and kidneys than Truvada, but those problems have only been seen in a small number of people taking Truvada, Walensky said.

She also noted that although Gilead scientists have presented some of their data at conferences, they have yet to publish their results in a peer-reviewed journal.

At a hearing in August, some activists urged the FDA to deny approval for use of Descovy in women or to require Gilead to test the drug in a large number of women promptly after approval.

Unless forced to do so by the FDA, critics said, the company has no motivation to test the drug in women.

“We had at least hoped that they would say something the day they approved it without an indication for women, that they would have a plan or forceful language laid out on how this disgraceful situation is going to be rectified,” Staley said.

Although the FDA’s announcement does not mention it, the agency is requiring such a study.

Brainard said Gilead plans to start the study in at least 1,500 high-risk women in southern Africa — where the incidence of HIV in women is higher than in the United States — by the end of 2020. The FDA’s approval letter requires the company to complete the trial by December 2024.

Walensky said she is disappointed by the numbers and timeline of that trial.

“I want to see a large-scale, rapid effort to get data in women as soon as possible,” she said. “That, in my mind, is the only way to rectify this.”
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
House Republicans Move to Defund OECD Over Global Tax Dispute
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
Intel Reports Revenue Beats but Sees 81% Rise in Losses
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
President Trump Diagnosed with Chronic Venous Insufficiency After Leg Swelling
CEO Resigns Amid Controversy Over Relationship with HR Executive
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
Tulsi Gabbard Unveils Evidence Alleging Political Manipulation of Intelligence During Trump Administration
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Trump Announces Coca-Cola to Shift to Cane Sugar in U.S. Production
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Air India Pilot’s Mental Health Records Under Scrutiny
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
Moonshot AI Unveils Kimi K2: A New Open-Source AI Model
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Proposes Supplying Arms to Ukraine Through NATO Allies
US Opens First Rare Earth Mine in Over 70 Years in Wyoming
Bitcoin Reaches New Milestone of $116,000
Severe Heatwave Claims 2,300 Lives Across Europe
Declining Beer Consumption Signals Cultural Shift in Germany
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
Western Europe Records Hottest June on Record
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
China’s Central Bank Consults European Peers on Low-Rate Strategies
France Requests Airlines to Cut Flights at Paris Airports Amid Planned Air Traffic Controller Strike
Poland Implements Border Checks Amid Growing Migration Tensions
Emirates Airline Expands Market Share with New $20 Million Campaign
Amazon Reaches Milestone with Deployment of One Millionth Robot
Yulia Putintseva Calls for Spectator Ejection at Wimbledon Over Safety Concerns
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
×